Presented by Joan Loken,

President Rocky Mountain Chapter

1

All stock references are meant to be used for educational purposes.

No recommendation for purchase or sale is intended or implied.

Please perform your own due diligence

2

Myriad Genetics, Inc., is engaged in the

discovery and commercialization of

transformative tests which ◦ assess a person's risk of developing disease, ◦

◦ guide treatment decisions and

◦ assess risk of disease progression and

recurrence.

4

Sector: Healthcare

Industry: Diagnostic & Research Services

HQ: Salt Lake City, UT

Sales: 550 Million (low end mid-sized)

Fiscal Year: ends June 30th

GROWTH: Organic with Partnerships and one major acquisition

5

CEO: Dr. Peter Meldrum

EMPLOYEES: 1169

incl. 45 PHD’s & 390 Sales

DEBT: None

Insider Ownership: 6.3%

Repurchased

24% of Shares Outstanding

6

7

8

9

10

11

12

13

14

Own or have license to 193 issued patents in US & foreign countries

Own or have license to 24 patents related to BRAC Analysis testing

Are party to multiple license agreements with rights to use certain technologies for ◦ Research, development of testing processes

◦ Commercialization of molecular diagnostic tests & diagnostic services

15

In 2011 acquired Rules Based Medicine (RBM)

Acquisition expanded test pipeline into new

diseases

Myriad RBM has strategic collaborations with 20

major pharmaceutical & biotechnology companies

Provide biomarker discovery & companion

diagnostic services

16

17

18

Provides companion diagnostic services to:

Pharmaceutical

Biotechnology industries

Medical research institutions

Can benefit from research performed by other organizations to acquire new product testing opportunities

19

20

21

22

23

May not be able to continue to license these

technologies on reasonable terms

Competition is intense in existing and potential

markets

Many potential competitors have greater financial,

technical & marketing resources

Existing molecular tests could be made obsolete

by less expensive or more effective test methods

in the future

24

Changes in healthcare policy

Foreign governments may

impose reimbursement standards

Unable to protect proprietary

technology

25

Defendant in lawsuit brought by Association for

Molecular Pathology on May 12, 2009

After bouncing around in the courts for four years,

now headed to the Supreme Court

U.S. Supreme Court hearing on April 15,

Decision by June 30, 2013

The lawsuit has affected the price of

Myriad stock

26

Link to NPR script of Supreme Court hearing and Justice’s comments http://www.npr.org/blogs/health/2013/04/15/177035299/supreme-court-asks-can-human-genes-be-patented

Wide coverage, read news articles at your

favorite site

Supreme Court Decision By June 30, 2013

27

28

29

30